🔗 Permalink

Inventor profile of:

Maxine BAUZON

City:

Hercules, California

Country:

United States

Published Applications:

Last publication date:

2025-06-12

Top Assignees for applications by Maxine BAUZON

The entities that hold a legal rights for patent applications filed by inventor BAUZON Maxine:

GLADIATOR BIOSCIENCES, INC. 7 Mill Valley, CA United States
Bayer HealthCare LLC 7 Whippany, NJ United States
Coagulant Therapeutics Corporation 3 Seoul, South Korea
Schering Aktiengesellschaft 2 Berlin, Germany
BAYER HEALTHCARE LLC 2 Tarrytown, NY United States
R.P. SCHERER TECHNOLOGIES, LLC 2 Carson City, NV United States
BAYER SCHERING PHARMA AKTIENGESELLSCHAFT 1 13353 Berlin, Germany

Recent patent applications by BAUZON Maxine

Maxine BAUZON from Hercules, US has applied for patents for these inventions. The list has both pending applications and granted patents:

#1 | 2025-06-12

US20250188189A1

Chemistry; metallurgy

HUMAN ANTIBODIES AGAINST ACTIVATED PROTEIN C AND USES THEREOF

#2 | 2025-05-22

US20250163183A1

Chemistry; metallurgy

CAMELID ANTIBODIES AGAINST ACTIVATED PROTEIN C AND USES THEREOF

#3 | 2025-05-15

US20250152724A1

Human necessities

ANTIBODY CONJUGATES SPECIFIC FOR MUCIN-1 AND METHODS OF USE THEREOF

#4 | 2025-04-17

US20250121083A1

Human necessities

Tumor-Associated Calcium Signal Transducer 2 (TACSTD2) Antibody-Maytansine Conjugates and Methods of Use Thereof

#5 | 2025-03-27

US20250101098A1

Chemistry; metallurgy

ANTIBODIES AND ANTIBODY CONJUGATES SPECIFIC FOR NECTIN-4 AND METHODS OF USE THEREOF

#6 | 2025-03-13

US20250084182A1

Chemistry; metallurgy

ANTIBODY SPECIFIC FOR MUCIN-1 AND METHODS OF USE THEREOF

#7 | 2024-10-17

US20240343818A1

Chemistry; metallurgy

Antibodies Having Humanized Framework Regions

#8 | 2023-09-21

US20230295596A1

Chemistry; metallurgy

SHORT-ACTING FACTOR VII POLYPEPTIDES

#9 | 2022-08-11

US20220251237A1

Chemistry; metallurgy

Antibody Specific for GPC3 and Methods of Use Thereof

#10 | 2022-02-03

US20220033514A1

Chemistry; metallurgy

Antibody specific for Mucin-1 and methods of use thereof

#11 | 2021-04-22

US20210113657A1

Human necessities

GLA DOMAINS AS TARGETING AGENTS

#12 | 2021-03-04

US20210062143A1

Chemistry; metallurgy

Method of targeting exosomes

#13 | 2021-01-21

US20210015900A1

Human necessities

GLA DOMAINS AS THERAPEUTIC AGENTS

#14 | 2021-01-07

US20210002624A1

Chemistry; metallurgy

Short-acting Factor VII polypeptides

#15 | 2020-12-31

US20200407422A1

Chemistry; metallurgy

A METHOD OF INTRACELLULAR DELIVERY

#16 | 2020-12-31

US20200407421A1

Chemistry; metallurgy

DELIVERY OF PAYLOADS TO STEM CELLS

#17 | 2019-04-11

US20190105370A1

Human necessities

GLA domains as therapeutic agents

#18 | 2017-10-19

US20170296624A1

Human necessities

GLA DOMAINS AS TARGETING AGENTS

#19 | 2016-12-29

US20160376578A1

Chemistry; metallurgy

Short-acting factor VII polypeptides

#20 | 2016-04-21

US20160106806A1

Human necessities

Gla domains as targeting agents

#21 | 2016-01-14

US20160008482A1

Human necessities

Gla domains as targeting agents

#22 | 2015-12-03

US20150344863A1

Chemistry; metallurgy

SHORT-ACTING FACTOR VII POLYPEPTIDES

#23 | 2015-10-29

US20150307625A1

Chemistry; metallurgy

MONOCLONAL ANTIBODIES AGAINST ACTIVATED PROTEIN C (aPC)

#24 | 2015-02-12

US20150044768A1

Chemistry; metallurgy

METHODS AND COMPOSITIONS FOR PRODUCTION OF RECOMBINANT PROTEIN IN HBX-EXPRESSING MAMMALIAN CELLS

#25 | 2014-12-11

US20140363419A1

Human necessities

Short-acting factor VII polypeptides

#26 | 2012-07-12

US20120178693A1

Chemistry; metallurgy

Cofactors for Thrombin Activation of Factor VII and Uses Thereof

#27 | 2011-11-10

US20110275121A1

Chemistry; metallurgy

Methods and compositions for production of recombinant protein in HBX-expressing mammalian cells

#28 | 2011-01-27

US20110020925A1

Chemistry; metallurgy

NEW MODULATING MOLECULES FOR AN IMPROVED REGULATED EXPRESSION SYSTEM

#29 | 2008-03-27

US20080076729A1

Chemistry; metallurgy

Interferon-beta gene therapy using an improved, regulated expression system

#30 | 2007-08-02

US20070179113A1

Human necessities

GM-CSF gene therapy for Crohn's disease using an improved regulated expression system

#31 | 2006-12-28

US20060292609A1

Chemistry; metallurgy

Interferon-beta gene therapy using an improved, regulated expression system

#32 | 2006-12-14

US20060281703A1

Chemistry; metallurgy

Treatment of disease using an improved regulated expression system

InventorID:

998797 ⎘